|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.0650 - 0.0650|
|52 Week Range||0.0650 - 0.0650|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced today that the registration statement on Form S-3, filed on May 4, 2022, was declared effective by the U.S. Securities and Exchange Commission, which includes a prospectus for an at-the-market equity offering under which the Company may offer and sell its Subordinate Voting Shares or common shares re-designated f
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today reported its financial results for the quarter ended March 31, 2022.
Key Takeaways; Cannabis Sector Glass House to acquires new California cannabis dispensaries for $22.6 million. Trulieve first quarter revenue increased 4% to $318.3 million; the company expects to sell over $1 billion of cannabis in 2022. Key Takeaways; Psychedelic Sector Awakn’s Prof. David Nutt and Prof. Celia Morgan gave exceptional presentations at Psych Symposium: London […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared first on Market Exclusive.